Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.
Copyright 2024 – Finance News Network
Source: Finance News Network
07 Apr 2025 - The Final Steps in Drug Development and Market Access
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More01 Mar 2024 - Shaw and Partners Chief Investment Office Martin Crabb discusses the leading indicators for equity markets, financial conditions and central banks.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More21 Oct 2019 - Kingston Resources Limited (ASX:KSN) CFO, Chris Drew, provides an update on the company's Misima and Livingstone gold projects and drill program.
Read More21 May 2021 - Hazer Group Limited (ASX:HZR) CEO & Managing Director Geoff Ward provides an update on the company's Commercial Development Project at the Woodman Point Wastewater Treatment Plant south of Perth, a 100 tonne per annum hydrogen production facility using waste gas produced through the water treatment facilities.
Read More26 Mar 2025 - The pros and cons of lithium and CERENERGY grid storage batteries
Read More29 Feb 2024 - Mitch Thomas - CFO - Latin Resources (ASX:LRS) is exploring and developing sustainable minerals in Australia and Latin America to provide the planet with environmentally friendly products.
Read More28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
Read More27 Jun 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company's lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.
Read More
